Jason Adair
Chief Business Officer
Replay available
Liquidia Corporation (NASDAQ: LQDA) Q1 2026 earnings conference call, held 2026-05-11. Replay captured from the company's public earnings webcast.

Chief Business Officer
Chief Executive Officer
Chief Operating Officer & Chief Financial Officer
Equity Research Analyst, Jefferies
General Counsel
Equity Research Analyst, Raymond James
Chief Commercial Officer
Equity Research Analyst, Needham & Company
Watch the replay and follow the connected company analysis, news, and investor updates for Liquidia Corporation.
WEBVTT 00:00:00.031 -- 00:00:05.338 Good morning and welcome to Liquidity Incorporation First Quarter 2026 Financial Results 00:00:05.338 -- 00:00:09.984 and Corporate Update Conference Call. My name is Jonathan and I will be your operator 00:00:09.984 -- 00:00:13.910 today. All participants are currently in a listen-only mode. 00:00:13.910 -- 00:00:17.915 Following the presentation, we will conduct a question and answer session. 00:00:17.915 -- 00:00:22.201 Instructions for joining the queue will be provided at that time. 00:00:22.201 -- 00:00:24.905 Please note that today's call is being recorded. 00:00:24.905 -- 00:00:31.891 And now I'd like to turn the call over to Jason Adair, the Quidius Chief Business Officer. 00:00:34.077 -- 00:00:34.738 You may proceed. 00:00:34.738 -- 00:00:39.343 Thank you and good morning, everyone. It's my pleasure to welcome you to our first quarter 00:00:39.343 -- 00:00:42.808 2026 Financial Results and Corporate Update call. 00:00:42.808 -- 00:00:47.716 Joining me today are Dr. Robert Jeffs, Chief Executive Officer, Michael Cassetta, Chief 00:00:47.716 -- 00:00:50.620 Operating Officer and Chief Financial Officer, Dr. 00:00:50.620 -- 00:00:55.746 Rajiv Sagar, Chief Medical Officer, Scott Mumal, Chief Commercial Officer, and Rusty 00:00:55.746 -- 00:00:58.310 Shundler, our General Counsel. 00:00:58.310 -- 00:01:02.235 Before we begin, please note that today's discussion will include forward-looking statements, 00:01:02.235 -- 00:01:06.801 including statements regarding future results, product performance, and ongoing clinical 00:01:06.801 -- 00:01:11.287 or commercial activities. These statements are subject to risks and uncertainties that 00:01:11.287 -- 00:01:14.180 may cause actual results to differ materially. 00:01:14.180 -- 00:01...